Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

Background. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015.

Methods. The study was performed in 43 centers during October–November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility.

Results. The reference population and the sample size were 38,904 and 1,588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend < .001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend < .001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend < .001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy.

Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.

Keywords. coinfection/epidemiology; hepatitis C/drug therapy/epidemiology; HIV infection/epidemiology; Spain/epidemiology.

Coinfection by hepatitis C virus (HCV) is one of the most common comorbidities in patients infected by the human immunodeficiency virus (HIV), particularly in areas in which HIV infection has been acquired through injection drug use (IDU) [1, 2]. However, since 2000, a substantial increase in the number of new HCV infections has been reported among men who have sex with men (MSM) involved in high-risk practices, particularly in metropolitan areas of Northern Europe, the United States of America, and Australia [3–5].
In the last few years, the introduction of direct-acting antiviral agents (DAAs) has revolutionized the treatment of HCV [6] and has provided new opportunities for treatment of coinfected individuals, a population considered to be difficult to treat in the interferon plus ribavirin era.

In countries like Spain, where sexually acquired HCV infection has contributed little to the burden of HIV/HCV coinfection to date, the prevalence of HCV antibodies and active HCV infection among HIV-infected individuals has decreased substantially over the years owing to several factors, including the decline in IDU as a mechanism of transmission of HIV infection, the greater mortality in HIV/HCV-coinfected patients than in HIV-monoinfected patients, and the increased uptake of anti-HCV treatment [7, 8]. All these factors provide strong arguments in favor of actively monitoring the burden of HIV/HCV coinfection. In this study, we present data from a nationwide prevalence study of HIV/HCV coinfection in Spain carried out in 2016.

**SUBJECTS AND METHODS**

The study was carried out by “Grupo de Estudio del SIDA” (AIDS Study Group; GeSIDA) of the “Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica” ([SEIMC] Spanish Society of Infectious Diseases and Clinical Microbiology) between October 1, 2016 and December 30, 2016 after a methodology similar to that used in 3 previous studies performed in 2002, 2009, and 2015 and reported in full elsewhere [7, 9, 10].

**Design and Sample Size Considerations**

This cross-sectional study was performed in 43 hospitals throughout Spain. The reference population was all HIV-infected patients in active follow-up in the participating centers. Active follow-up was defined as at least 1 visit to the center in the previous 12 months. Before the study was initiated, the total number of patients in active follow-up at the participating centers was 38,904 and the prevalence of active HCV infection was 22.1%, according to the most recent survey carried out by GeSIDA in 2015 [7]. Based on these figures, a confidence level of 95%, a design effect of 1.0, and an accuracy for the sample size of 2.0%, we estimated that a sample of at least 1588 patients was needed.

**Patient Selection**

The number of patients to be included at each center was determined by proportional allocation, and patients were selected by simple random sampling (full details in [7]). The Institutional Ethics Committee of Hospital General Universitario Gregorio Maraño approved the study and waived the requirement for written informed consent, because the study was based on anonymous routine clinical data intended for scientific publication.

**Variables and Statistical Analysis**

We collected demographic data, HIV transmission category, Centers for Diseases Control and Prevention (CDC) disease category, current CD4+ T-cell counts, current HIV-ribonucleic acid (RNA), whether patients were on combination antiretroviral therapy (cART), and the regimen used. We also inquired about the presence of hepatitis B virus surface antigen (HBsAg), the presence of HCV antibodies, and—if applicable—the presence of HCV-RNA. In patients with HCV antibodies, information was also obtained about anti-HCV therapy and—if applicable—the regimens used and their outcomes. Patients receiving anti-HCV therapy at the time the study was performed were considered to be HCV-RNA positive. In the case of patients with HCV antibodies and negative HCV-RNA, we inquired whether this was due to spontaneous clearance or to anti-HCV treatment. In patients with HCV antibodies and who were HCV-RNA positive, we collected HCV genotype and subtype. In patients who were positive for HCV-RNA and/or HBsAg, transient elastography results and the date the procedure were performed were recorded.

The presence of liver cirrhosis was investigated in all patients, as was the method of diagnosis, namely, liver biopsy, transient elastography (liver stiffness >12.5 kPa), or clinical/biological findings. Patients with prior or current episodes of ascites, hepatic encephalopathy, or variceal bleeding were considered to have decompensated liver disease. In patients with cirrhosis, current Child-Pugh and Model for End-Stage Liver Disease (MELD) scores were recorded. We also recorded whether patients had been diagnosed with hepatocellular carcinoma and whether they had undergone liver transplantation. We calculated anti-HCV treatment uptake, defined as the percentage of patients with current or past chronic HCV infection exposed to anti-HCV therapy.

All the information was entered into a shared database at each institution using an online electronic case report form. A descriptive analysis was carried out using frequency tables for categorical variables and mean and standard deviation (SD) or median and interquartile range (IQR) for normally or nonnormally distributed continuous variables. We used the χ² test of independence to detect significant differences in categorical variables and the t test or the nonparametric Mann-Whitney test for differences in normally or nonnormally distributed continuous variables, respectively. All statistical analyses were performed using Stata, version 14.0 (StataCorp, College Station, TX).

**RESULTS**

A total of 43 centers participated in the study. The reference population was 38,904 HIV-infected patients, and the sample size was 1588 patients.

**Patients’ Characteristics**

The characteristics of the 1588 patients included in the study are summarized in Table 1. No significant differences were found for sex between HCV-seronegative and HCV-seropositive patients; however, the latter were 4 years older than the former, on average. The frequency of IDU was significantly higher among...
HCV-seropositive patients than among HCV-seronegative patients, whereas the frequency of both transmission via heterosexual relations and sexual relations between MSM was significantly higher among HCV-seronegative than among HCV-seropositive patients. Hepatitis B virus surface antigen positivity was more frequent in HCV-seronegative patients than in HCV-seropositive patients (4.4% vs 2.5%; \( P < .019 \)).

More HCV-seropositive patients were in CDC category C than HCV-seronegative patients (30.3% vs 22.8%; \( P < .001 \)). Overall, 96.7% of patients were on cART. In comparison with HCV-seronegative patients, a small but significantly higher proportion of HCV-seropositive patients were on cART (98.2% vs 95.8%, respectively; \( P = .014 \)). In comparison with HCV-seronegative patients, a significantly lower proportion of HCV-seropositive patients were receiving a first-line ART regimen (22.9% vs 7.2%, respectively; \( P < .001 \)). The proportion of patients with an HIV-RNA load <50 copies/mL was 89.5% overall and 92.2% in patients receiving cART. Among the latter, no significant differences were found between HCV-seropositive and HCV-seronegative patients. In the full data set, statistically significantly lower CD4+ T-cell counts were found among HCV-seropositive patients than among HCV-seronegative patients (671 vs 654 cells/µL; \( P = .045 \)) and in patients on cART (678 vs 659 cells/µL; \( P = .039 \)), although the differences were small.

**Prevalence of Anti-Hepatitis C Virus (HCV) Antibodies and Active HCV Infection**

Hepatitis C virus serostatus was known in 1585 (99.8%) patients, 548 of whom were HCV seropositive. Of these 548 patients, 186 were HCV-RNA positive, 292 were HCV-RNA negative after sustained viral response after anti-HCV therapy, 68 cleared HCV spontaneously, and HCV-RNA results were unknown in 2.

The prevalence of anti-HCV antibodies was therefore 34.6% among tested patients (548 of 1585 patients whose serostatus was known), and the prevalence of active HCV infection was 11.7% (186 of 1583 patients with known HCV serostatus and with known HCV-RNA among those with HCV antibodies).

**Comparison With Previous Prevalence Studies**

We compared the results of this study with those of 3 national studies carried out by GeSIDA in 2002, 2009, and 2015 in a similar number of centers across the same geographical areas of Spain [7, 9, 10]. A summary of participating centers, reference population, and sample size of the studies performed in 2002, 2009, 2015, and 2016 is shown in Table 2.

The main HIV transmission categories among HIV-infected individuals in the 4 prevalence studies are shown in Figure 1. From 2002 to 2015, there was a significant decrease in the proportion of IDU (from 55.2% to 30.7%) and a significant increase in the proportion of MSM (from 17.2% to 35.1%). However, no significant changes were observed from 2015 to 2016.

The prevalence of anti-HCV antibodies and the prevalence of active HCV infection in the 4 studies are shown in Figure 2. The prevalence of anti-HCV antibodies decreased significantly from 60.8% in 2002 to 37.7% in 2015 (\( P \) trend < .001) and remained almost unchanged in 2016 (34.6%). In addition, the prevalence of active HCV infection decreased significantly from 54.0% in 2002 to 11.7% in 2016 (\( P \) trend < .001). Of note, a 47.1% reduction in the prevalence of active HCV infection was observed from 2015 to 2016. In contrast, the decrease in the prevalence of active HCV infection was 37.0% in the 8-year period from 2002 to 2009 and 35.0% in the 7-year period from 2009 to 2015.

**Anti-HCV treatment uptake in the 4 prevalence studies is shown in Figure 3. The proportion of patients with current or past chronic HCV infection exposed to anti-HCV therapy increased significantly from 23.0% in 2002 to 74.7% in 2016.**

**Characteristics of Patients With Active Hepatitis C Virus Infection**

The characteristics of the 186 patients with active HCV infection are summarized in Table 3. A total of 121 (65.1%) were naïve for anti-HCV therapy, and 41 (22.0%) were receiving oral DAA therapy during the study. Two patients (1.1%) with active HCV infection had reinfections after sustained viral response with pegylated interferon plus ribavirin. The HCV genotype was unknown in 10 patients (5.4%). Among the remaining 176 patients, the most common infecting genotypes were 1a (46.6%), 4 (22.2%), 3 (15.9%), and 1b (13.6%). Transient elastography was performed in 150 patients (80.6%) a median of 10 months before data were collected. The median liver stiffness value was 6.6 kPa. The distribution of liver stiffness by cutoff was as follows: <7.1 kPa (absent or mild liver fibrosis), 58.0%; >9.5 kPa (advanced fibrosis), 23.3%; and >12.5 kPa (cirrhosis), 16.0% [11]. In addition, the fibrosis-4 (FIB-4) score was available for 185 (99.5%) patients, 13.0% of whom had values ≥2.35 (indicative of advanced liver fibrosis) [12].

The main features of liver cirrhosis in patients with active HCV infection and in those who cleared HCV infection after anti-HCV therapy are summarized in Table 4. Liver cirrhosis was present in 28 of 186 (15.0%) patients with active HCV infection and in 92 of 292 (31.5%) patients who cleared HCV after anti-HCV therapy. Thus, we can assume that of the 1588 HIV-infected patients included in the study, a diagnosis of HCV-related liver cirrhosis had been made at some point in 120 (7.6%) patients.

**DISCUSSION**

This study showed that at the end of 2016, the prevalence of active HCV infection among HIV-infected individuals in Spain was 11.7%. This represents an approximately 50% decrease in comparison with the prevalence found in 2015. This sharp decrease occurred concurrently with increased access to oral DAA treatments for HCV. The study also showed that approximately 7.6% of all HIV-infected individuals in Spain had HCV-related cirrhosis, a condition that was twice as common in coinfected patients with a sustained viral response than in those with active HCV infection.
### Table 1. Baseline characteristics of the 1588 Patients Included in the Study

| Characteristic | Unknown | HCV Antibodies | Positive | Negative | Total |
|---------------|---------|----------------|----------|----------|-------|
| Male sex, n (%) | 3 (100.0) | 140 (75.3) | 233 (79.8) | 41 (60.3) | 1 (50.0) | 415 (75.7) | 805 (77.6) | .39 | 1223 (77.0) |
| Age years, mean (SD) | 51 (4) | 50 (7) | 52 (6) | 51 (8) | 50 (5) | 51 (7) | 47 (12) | <.001 | 49 (11) |
| Injection drug use | 0 | 140 (75.3) | 231 (79.1) | 44 (64.7) | 2 (100.0) | 417 (76.1) | 53 (5.1) | <.001 | 470 (29.6) |
| Heterosexual | 0 | 22 (11.8) | 22 (7.5) | 14 (20.6) | 0 | 58 (10.6) | 318 (30.7) | 376 (23.7) |
| Men who have sex with men | 3 (100.0) | 12 (6.4) | 14 (4.8) | 4 (5.9) | 0 | 30 (5.0) | 523 (50.4) | 556 (35.0) |
| Contaminated blood products | 0 | 2 (1.1) | 2 (0.7) | 0 | 0 | 4 (0.7) | 1 (0.1) | 5 (3.0) |
| Mother-to-child transmission | 0 | 2 (1.1) | 0 | 1 (1.5) | 0 | 3 (0.5) | 8 (0.8) | 11 (0.7) |
| Other | 0 | 8 (4.3) | 23 (7.9) | 5 (7.3) | 0 | 36 (6.6) | 134 (12.9) | 170 (10.7) |
| HBsAg, n (%) | 1 (33.3) | 171 (91.9) | 278 (95.2) | 64 (94.1) | 2 (100.0) | 515 (94.0) | 973 (93.8) | .019 | 1489 (93.8) |
| Positive | 0 | 5 (2.7) | 5 (1.7) | 4 (5.9) | 0 | 14 (2.5) | 46 (4.4) | 60 (3.8) |
| Unknown | 2 (66.7) | 10 (5.4) | 9 (3.1) | 0 | 0 | 19 (3.5) | 18 (1.7) | 39 (2.5) |
| CDC clinical category C, n (%) | 54 (29.0) | 92 (31.5) | 20 (29.4) | 166 (30.3) | 236 (22.8) | .001 | 402 (25.3) |
| cART, n (%) | 3 (100.0) | 181 (97.3) | 289 (99.0) | 66 (97.1) | 2 (100.0) | 538 (98.2) | 994 (95.8) | .014 | 1535 (96.7) |
| Type of cART regimen, n (%) | 2 NRTI + 1 NNRTI | 1 (33.3) | 45 (24.9) | 75 (25.9) | 16 (24.2) | 0 | 136 (25.2) | 376 (37.8) | <.001 | 513 (33.4) |
| 2 NRTI + 1 PI | 0 | 32 (17.7) | 31 (10.7) | 9 (13.6) | 1 (50.0) | 74 (13.7) | 118 (11.9) | 191 (12.4) |
| 2 NRTI + 1 integrase inhibitor | 2 (66.7) | 61 (33.7) | 101 (34.9) | 21 (31.8) | 0 | 183 (33.9) | 312 (31.4) | 497 (32.4) |
| PI-based monotherapy | 0 | 13 (7.2) | 19 (6.6) | 4 (6.1) | 0 | 36 (6.7) | 49 (4.9) | 85 (5.5) |
| PI-based bitherapy | 0 | 15 (8.3) | 30 (10.4) | 8 (12.1) | 0 | 53 (9.8) | 56 (5.6) | 109 (7.1) |
| Other | 0 | 15 (8.3) | 33 (11.4) | 8 (12.1) | 1 (50.0) | 57 (10.6) | 83 (8.3) | 140 (9.1) |
| Category of cART regimen, n (%) | 0 | 15 (8.3) | 17 (5.9) | 7 (10.6) | 0 | 39 (72) | 228 (22.9) | <.001 | 267 (17.4) |
| First-line therapy | 1 (33.3) | 100 (55.2) | 168 (58.1) | 28 (42.4) | 1 (50.0) | 298 (55.3) | 436 (43.9) | 734 (47.8) |
| Switch unrelated to toxicity/failure | 0 | 24 (13.3) | 19 (6.6) | 8 (12.1) | 1 (50.0) | 52 (9.6) | 60 (6.0) | 112 (7.3) |
| Switch after failure | 2 (66.7) | 40 (22.1) | 80 (27.7) | 22 (33.3) | 0 | 142 (26.3) | 240 (24.1) | 384 (25.0) |
| Unknown | 0 | 2 (1.1) | 5 (1.7) | 1 (1.5) | 0 | 8 (1.5) | 30 (3.0) | 38 (2.5) |
| HIV-RNA copies/mL, n (%) | 3 (100.0) | 158 (84.9) | 276 (94.5) | 57 (83.8) | 2 (100.0) | 493 (90.0) | 926 (89.3) | .15 | 1422 (89.5) |
| All patients | 0 | 7 (3.8) | 9 (3.1) | 7 (10.3) | 0 | 23 (4.2) | 30 (2.9) | 53 (3.3) |
| Patients on cART | 0 | 21 (11.3) | 7 (2.4) | 4 (5.9) | 0 | 32 (5.8) | 81 (78) | 113 (7.1) |
| <50 | 3 (100.0) | 157 (86.7) | 273 (94.5) | 56 (84.8) | 2 (100.0) | 488 (90.7) | 924 (93.0) | .28 | 1415 (92.2) |
| 50–200 | 0 | 7 (3.9) | 9 (3.1) | 7 (10.6) | 0 | 23 (4.2) | 30 (2.9) | 53 (3.4) |
| >200 | 0 | 17 (9.4) | 7 (2.4) | 3 (4.5) | 0 | 27 (5.0) | 40 (4.0) | 67 (4.4) |

**Abbreviations:** cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; RNA, ribonucleic acid; SD, standard deviation.

*P* values for the comparisons between HCV-positive patients (n = 548) and HCV-negative patients (n = 1037) derived from the χ² test for independence for categorical variables and the t test or the Mann-Whitney test for normally or nonnormally distributed continuous variables, respectively.
The results of this study and previous GeSIDA studies [7, 9, 10] showed remarkable differences between the seroprevalence of HCV and the prevalence of active HCV infection among HIV-infected individuals in the 14-year period from 2002 and 2016. The seroprevalence of HCV dropped sharply from 2002 to 2015 but remained practically unchanged from 2015 to 2016 (approximately 35%). However, the prevalence of active HCV infection decreased steadily from 54.0% in 2002 to 11.7% in 2016. Of note, a 47% drop was observed from 2015 to 2016. This is a huge decrease if we consider that the decline in the prevalence of active HCV infection was 37.0% in the 8-year period from 2002 to 2009 and 35.0% in the 7-year period from 2009 to 2015, respectively.

Several factors contributed to the declining trends in HCV seropositivity and active infection among HIV-infected individuals from 2002 to 2016. In the early years, the main factor was the reduction in the frequency of IDU as a mechanism of HIV transmission [13], together with the development of preventive drug programs [14]. The higher mortality rates in coinfected patients compared with HIV-monoinfected patients in this period also contributed to a decrease in the prevalence of HCV infection [15]. Over the last few years, however, the reduction of active HCV infection may be attributable to the increase in the frequency of anti-HCV treatment uptake, which went from 23.0% in 2002 to 59.3% and 74.7% in 2015 and 2016, respectively. Of note, in the last 2 years, anti-HCV therapy in Spain consisted of DAA-based regimens. Under real-life conditions, these regimens yielded high rates of sustained viral response that were similar to those of HCV-monoinfected patients and showed an excellent safety and tolerance profile, even in patients with end-stage liver disease [16, 17].

All of the above findings raise the question of whether the goal of elimination of HCV among HIV-infected individuals can be achieved in Spain in the short term. Elimination of an infection means the reduction to zero of the incidence of the disease caused by a specific agent in a defined geographical area because of deliberate efforts, requiring continued measures to prevent re-establishment of transmission [18]. If one considers that prevention, screening, and universal access to treatment are essential for the elimination of HCV infection [19], Spain appears to be on the right track towards the achievement of this goal.

As previously mentioned, the preventive programs of the National Drug Strategy in Spain have proven effective for reduction of drug-related risk and harm [14]. These programs have included social and health services offering preventive educational interventions, overdose prevention activities, sterile needles and syringes, testing for drug-related infections, vaccination against viral hepatitis, emergency care and assistance to injecting drug users (who do not usually have contact with support interventions), and a scaling up of opioid substitution treatment. The National Drug Strategy for the period 2017–24 covers many illicit and licit substances [14]. As this and previous studies show, HCV infection acquired through sexual relations contributes little to the burden of coinfection in Spain and

![Figure 1](https://example.com/image1.png)

**Figure 1.** Principal human immunodeficiency virus transmission categories in the cross-sectional studies carried out by Grupo de Estudio del SIDA in 2002, 2009, 2015, and 2016. IDU, injection drug use; MSM, men who have sex with men.

![Figure 2](https://example.com/image2.png)

**Figure 2.** Prevalence of hepatitis C virus (HCV) seropositivity and active HCV infection in the cross-sectional studies carried out by Grupo de Estudio del SIDA in 2002, 2009, 2015, and 2016. HCV Ab+, presence of antibodies against HCV; HCV-RNA+, detectable HCV-RNA; RNA, ribonucleic acid.

---

**Table 2. Centers and Patients Included in the Nationwide HCV Prevalence Studies Carried out by GeSIDA in 2002, 2009, 2015, and 2016**

| Variable                  | 2002 | 2009 | 2015 | 2016 |
|---------------------------|------|------|------|------|
| Participating centers     | 39   | 43   | 41   | 43   |
| Reference population      | 31800| 29559| 35791| 38904|
| Sample size               | 1260 | 1458 | 1867 | 1588 |
| Tested for HCV antibodies | 99.5%| 99.8%| 98.7%| 99.8%|
| Reference                 | 9    | 10   | 7    | Current study

**Abbreviations:** GeSIDA, Grupo de Estudio del SIDA; HCV, hepatitis C virus; IQR, interquartile range; RNA, ribonucleic acid; TE, transient elastography.
remains restricted to specific areas of Madrid and Barcelona [20, 21]. However, prevention activities should also be undertaken to reduce high-risk behavior among both HIV-infected and non-HIV-infected MSM who engage in high-risk practices for sexual transmission of HCV [5].

Hepatitis C virus screening practices among HIV-infected individuals appear to be of a high standard according to the results of the 4 prevalence studies performed over the last 14 years, which have consistently shown that 99% of HIV-infected individuals are tested for HCV antibodies [7]. However, it is important to perform regular screening for HCV among HIV-infected people who engage in high-risk practices. In addition, testing should be considered in migrants from regions with a high prevalence of HCV, such as sub-Saharan Africa and Eastern Europe [22, 23].

As for universal access to therapy, a total of 63,075 patients with HCV—20% of whom were coinfected—were treated with all oral DAA-based regimens in Spain from January 1, 2015 to September 31, 2016 [24]. During the first months, access to therapy was prioritized for patients with advanced liver fibrosis or cirrhosis; however, in 2015, in most autonomous regions of Spain, access to DAA therapy was available for patients with significant fibrosis (METAVIR F ≥2 in liver biopsy or equivalent by transient elastography). Furthermore, irrespective of liver fibrosis stage, DAA-based therapy could also be administered to patients with clinically significant extrahepatic manifestations of HCV (such as symptomatic mixed cryoglobulinemia) and to patients at risk of transmitting HCV (active injection drug users, MSM with high-risk sexual practices for acquiring HCV, and women of childbearing age who wish to become pregnant).

In June 2017, the Spanish Ministry of Health committed to providing access to DAA-based therapy for all individuals with HCV, irrespective of the stage of fibrosis [25].

An important observation in this study was the finding that almost 8% of all HIV-infected individuals had been diagnosed at some time with HCV-related liver cirrhosis. Of note, cirrhosis was more common in patients who had achieved a sustained viral response than in those with active HCV infection. This finding underscores the fact that despite the well known benefits of eradicating HCV among coinfected individuals in terms of reduced morbidity and mortality [26], there persists a residual risk for liver-related events, especially hepatocellular carcinoma, in patients with cirrhosis in whom HCV has been eradicated [27, 28]. Therefore, even if we achieve the probable and desired goal of eliminating HCV among HIV-infected individuals, the burden of HCV-related cirrhosis will remain

### Table 3. Characteristics of Liver Disease in the 186 Patients Who Were HCV-RNA Positive

| Characteristic                                      | N = 186 |
|----------------------------------------------------|---------|
| **Anti-HCV Therapy, n (%)**a                        |         |
| Never                                              | 121 (65.1) |
| Ongoingb                                           | 41 (22.0)  |
| In the past                                         | 34 (18.3)  |
| Null response or partial response                   | 26 (76.5)  |
| Relapse                                            | 1 (2.9) |
| Abandonment or interruption due to adverse events  | 5 (14.7)  |
| Sustained viral response                           | 2 (5.9) |
| **HCV Genotype, n (%)**                             |         |
| Unknown                                            | 10 (5.4)  |
| Known                                              | 176 (94.6) |
| 1a                                                 | 82 (46.6) |
| 4                                                  | 39 (22.2) |
| 1b                                                 | 24 (13.6) |
| 3                                                  | 28 (15.9) |
| 2                                                  | 3 (1.7) |
| Mixed                                              | 0 |
| **TE Results**                                     |         |
| Patients with TE, n (%)                            | 150 (80.6) |
| Months from TE to study date, median (IQR)         | 10.0 (5.6–21.9) |
| TE value–kPa, median (IQR)                         | 6.6 (5.4–9.1) |
| TE distribution according to cutoff values–kPa, n (%) |         |
| <7.1                                               | 87 (58.0) |
| 7.1–9.5                                            | 28 (18.7) |
| 9.6–12.5                                           | 11 (7.3) |
| >12.5                                              | 24 (16.0) |
| **FIB-4 Index Results**                            |         |
| Patients with FIB-4, n (%)                         | 185 (99.5) |
| FIB-4 value, median (IQR)                          | 1.5 (1.1–2.2) |
| FIB-4 Distribution According to Cutoff Values, n (%) |         |
| ≤1                                                 | 39 (21.1) |
| 1–3.25                                             | 122 (65.9) |
| ≥3.25                                              | 24 (13.0) |

Abbreviations: DAA, direct-acting antiviral agent; FIB-4, fibrosis 4; HCV, hepatitis C virus; IQR, interquartile range; RNA, ribonucleic acid; TE, transient elastography.

The number of patients in the “never,” “ongoing,” and “in the past” categories total more than 186 because of the groups overlap. Of the 186 patients, 121 were naive for anti-HCV therapy, 31 are currently receiving therapy but had not received it previously, 24 are not currently receiving therapy but had received it in the past, and 10 are currently receiving treatment and received it in the past.

bAll 41 patients in this category were receiving oral DAA therapy during the study.

---

**Figure 3.** Anti-hepatitis C virus (HCV) treatment uptake in the cross-sectional studies carried out by Grupo de Estudio del SIDA in 2002, 2009, 2015, and 2016. Treatment uptake was defined as the proportion of patients with current or past chronic HCV infection exposed to anti-HCV therapy.
sharp increase in the uptake of oral DAAs against HCV. We believe with the prevalence for 2015. This decrease was accompanied by a prevalence of active HCV infection among HIV-infected individuals substantial. Considering the 130,000 to 160,000 people who live with HIV in Spain [29] and the 7.6% prevalence of HCV-related cirrhosis, between 9120 and 12,160 HIV-infected individuals who have men who have sex with men: a case-control study. Open Forum Infect Dis 2017; 3: ofw059.
8. European Monitoring Centre for Drugs and Drug Addiction. Harm reduction overview for Spain. Available at: http://www.emcdda.europa.eu/country-data/harm-reduction/Spain. Accessed 15 June 2017.
9. González-García JJ, Mahillo B, Hernández S, et al. [Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. Enferm Infecc Microbiol Clin 2005; 23:340–8.
10. González-García J, Navarro C, Condes E, et al. [Evolución de la prevalencia de la coinfección por VHC, características de la hepatopatía y tratamiento específico en pacientes infectados por VIH en España. Estudio Gesida 57/07]. Abstract No. PO–41. IV Congreso Nacional de Gesida, Toledo, Spain, November 27–30, 2012.
11. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835–47.
12. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317–25.
13. Perez Cañadura S, Del Amo J, Iribarren JA, et al. Decrease in seral prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997–2006. Clin Infect Dis 2009; 48:1467–70.
14. European Monitoring Centre for Drugs and Drug Addiction. Spain Country Drug Report 2017. Available at: http://www.emcdda.europa.eu/system/files/publications/4525/TDD0116922EN.pdf. Accessed 17 July 2017.
15. Berenguer J, Alejos B, Hernando V, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 2012; 26:2241–6.
16. Gil-Martín A, González-García J, Cruz-Martos E, et al. Real-World Outcomes With New HCV Antivirals in HIV/HCV-Coinfected Subjects: Madrid Coinfection...
Registry (Madrid-CoRE) Findings. Abstract 78. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. Boston, November 11–15, 2016.

17. Montes ML, Oliveira A, Ahamada A, et al. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS 2017; 31:1253–60.

18. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998; 76(Suppl 2):23–5.

19. Buckley GI, Strom BL. A national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C. Ann Intern Med 2017; 166:985–6.

20. Montoya-Ferrer A, Fierer DS, Alvarez-Alvarez B, et al Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. Emerg Infect Dis 2011; 17:1560–2.

21. Martinez-Rebollar M, Malloks J, Pérez I, et al. Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients. Infecte Immun Microbio Clin 2015; 33:3–8.

22. European Centre for Disease Prevention and Control (ECDC). Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA. Stockholm, Sweden: ECDC, 2014.

23. Carballo M, Maclean EC, Giudumac I, Van Damme P. Hepatitis C and migration: a public health challenge. J Fam Med 2016; 3: 1065.

24. Secretaría General de Sanidad y Consumo Ministerio de Sanidad SSeI. [Información del Plan Estratégico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud (Noviembre 2016)]. 2016.

25. Ministerio de Sanidad Servicios Sociales e Igualdad. [Nota de Prensa del Pleno del Consejo Interterritorial del Sistema Nacional de Salud]. Available at: http://www. actasanitaria.com/wp-content/uploads/2017/06/21.06.2017-np-consej o-interterritorial-de-salud.pdf. Accessed 31 July 2017.

26. Berenguer J, Rodríguez-Castellano E, Carrero A, et al. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017; 66:344–56.

27. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with historically advanced chronic hepatitis C. Hepatology 2010; 52:833–44.

28. van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017; 66:485–93.

29. Plan Nacional sobre el Sida. Dirección General de Salud Pública Calidad e Innovación. [Vigilancia Epidemiológica del VIH y sida en España - Actualización 30 de Junio de 2016]. Available at: https://www.msssi.gob.es/ciudadanos/encuestas/en/cientes/vigilancia/InformeVIH_SIDA_2016.pdf. Accessed 31 July 2017.

30. Kanwal F, Bacon BR, Beste LA, et al. Hepatitis C virus infection care pathway—a report from the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology 2017; 152:1588–98.

31. Jacobson IM, Lim JK. Fried MW. American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology 2017; 152:1578–87.

APPENDIX: THE GESIDA 8514 STUDY GROUP

Hospital Gregorio Marañón, Madrid: L. Pérez- Latorre, P. Miralles, J. C. López, F. Parras, B. Padilla, T. Aldázmiz, A. Carrero, C. Diez, F. Tejerina, C. Fanciulli, and J. Berenguer. Hospital La Paz, Madrid: M. J. Núñez, F. Arnalich, J. R. Arribas, J. I. Bernardino, J. González-García, V. Hontaño, M. L. Martín- Carbonero, R. Micán, R. Montejo, M. L. Montes, V. Moreno, I. Pérez- Valero, C. Navarro, E. Valencia, and J. González-García. Hospital Universitario Reina Sofía, Córdoba: A. Rivero-Juárez, T. Brieva, I. Machuca, A. Camacho, and A. Rivero-Román. Instituto de Salud Carlos III, Madrid: I. Jarrin. Hospital Ramón y Cajal, Madrid: M. J. Vivancos, S. Moreno, A. Moreno, J. L. Casado, M. J. Pérez-Ellas, and C. Quereda. Hospital Vall d’Hebrón, Barcelona: A. Torrella, B. Planas, and J. Navarro. Hospital Clínico San Carlos, Madrid: M. Rodrigo, V. Estrada, J. Vergas, and M. J. Téllez. Hospital Santa Creu i Sant Pau, Barcelona: J. Muñoz, M. Gutiérrez, G. Mateo, and J. M. Guardiola. Hospital Donostia, San Sebastián: M. Ibarguren, M. P. Carmona, F. Rodríguez-Arrondo, M. A. Goenaga, H. Azkune, M. A. Von Wichmann, and J. A. Iriarren. Hospital Doctor Peset, Valencia: J. Carmena and A. Artero. Hospital Universitario Álvaro Cunqueiro, Vigo: E. Prado-González, G. Piera-Rojo, A. Ocampa, C. Miralles, M. Crespo, and L. Morano. Hospital Virgen de la Victoria, Málaga: J. Ruiz, E. Nuño, R. Palacios, J. Santos, and M. Márquez. Hospital de la Princesa, Madrid: J. Sanz and I. Santos. Hospital Miguel Servet, Zaragoza: J. Moreno and P. Arazo. Hospital La Fe, Valencia: M., Montero, M. Tasías, S. Cuellar, E. Calabuig, M. Blanes, J. Fernández, J. López-Aldeguer, and M. Salavert. Hospital 12 de Octubre, Madrid: A. Hernando, L. Domínguez, O. Bisbal, M. De Lagarde, M. Matarranz, R. Rubio, and E. Pulido. Hospital Virgen de las Nieves, Granada: C. García. Hospital University Marques de Valdecilla, Santander: C. Armíñanzas, S. Echevarría, M. Gutiérrez-Cuadra, and C. Fariñas. Hospital General de Alicante, Alicante: L. Giner, S. Reus, E. Merino, V. Boix, D. Torrós, I. Portilla, M. Pampliega, M. Diez, I. Egea, and J. Portilla. Hospital Universitario Basurto, Bilbao: O. L. Ferrero, S. Ibarra, I. López, M. de la Peña, Z. Zubero, J. Baraia, and J. Muñoz. Hospital Príncipe de Asturias, Alcalá de Henares: J. de Miguel, A. Arranz, E. Casas, and J. Sanz. Hospital Clínico de Valencia, Valencia: A. Ferrer and M. J. Galindo. Hospital San Pedro—CIBIR, Logroño: L. García, L. Pérez, and J. A. Oteo. Hospital Fundación de Alcorcón, Alcorcón: M. Velasco, L. Moreno, R. Hervás, and J. E. Losa. Complejo Hospitalario Universitario de Granada, Granada: D. Vinuesa, L. Muñoz, and J. Hernández-Quero, Hospital Universitario de Tarragona Joan XXIII, Tarragona: S. Veloso, J. Peraire, C. Viladés, M. Vargas, A. Castellano, and F. Vidal. Hospital San Eloy-OSI, Baracaldo: R. Silvañiño. Hospital Virgen de la Cinta, Tortosa: A. J. Ortí, E. Chamorro, and C. Escrig. Hospital Virgen de la Luz, Cuenca: P. Geijo. Hospital Virgen de la Concha, Zamora: A. Chocarro. Centro Sanitario Sandoval, Madrid: C. Rodríguez, T. Puerta, M. Raposo, M. Vera, and J. Del Romero. Hospital d’Olot i Comarcal de la Garrotxa, Olot: J. Bisbe. Hospital Son Llàtzer, Palma de Mallorca: C. Cifuentes. Hospital de Sierra llana, Torrelavega: R. Teira. Hospital Universitari de Vic, Vic: J. Vilaró. Hospital Infanta Elena, Valdemoro: A. Vega. Hospital Reina Sofia, Murcia: A. Cano, A. Alcaráz, A. Muñoz, and E. Bernal. Hospital de Cabueñas, Gijón: M. Camponmor, M. J. Tuya, and B. de la Fuente. Hospital Universitario de Torrejón: Torrejón de Ardoz: A. Gimeno, C. Montero, and S. Arponen. Hospital de Mataró, Mataró: L. Force and P. Barrufet. Hospital Universitario de Getafe, Getafe: G. Gaspar. Hospital Rafael Méndez, Lorca: G. Alonso, C. Toledo, A. I. Peláez, G. Lara, I. Fernández, and M. C. Esteban.